ICU Medical (ICUI) Stock Forecast & Price Target

ICU Medical is well positioned because its consumables-heavy, largely recurring revenue base serves a structurally defensive IV market, while its top-tier positions in consumables, infusion systems, and vital care support durable demand and share gains. The company’s 2Q results showed revenue of $548M, adjusted EBITDA of $110M, and adjusted EPS of $2.37, with record consumables and infusion systems sales driving margin expansion and prompting guidance to rise to $415M-$435M of adjusted EBITDA and $8.60-$9.00 of adjusted EPS. Its financial profile is also improving, as free cash flow of $62M enabled a $50M debt paydown and reduced net leverage to 2.3x, while manufacturing synergies, lower tariffs, and a meaningful pump replacement cycle create further upside.

ICU Medical is facing a negative setup because its growth remains uneven: 2Q26 revenue growth improved to 6% from 1Q26, but that was driven mainly by Consumables and Infusion Systems while Vital Care still declined 4% and missed consensus at $70M. The bull case depends on improving execution and regulatory progress, yet there is clear risk from pulled-forward pump installations, an amended 510(k) still needing FDA submission later this year, and potential gross margin pressure from inflation, tariffs, or pricing headwinds. With bear case assumptions calling for only low-single-digit revenue growth and limited operating margin improvement, the company may struggle to deliver meaningfully stronger earnings if hospital demand, contract renewals, or FDA timelines disappoint.